4892 — Cyfuse Biomedical KK Balance Sheet
0.000.00%
Last trade - 00:00
- ¥6bn
- ¥3bn
- ¥61m
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final |
Cash and Equivalents | ||||
Cash and Short Term Investments | 2,073 | 2,413 | 4,437 | 3,874 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 37.2 | 57.7 | 69.8 | 49.8 |
Total Inventory | ||||
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 2,152 | 2,559 | 4,565 | 3,987 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 32.9 | 27.3 | 189 | 170 |
Net Intangible Assets | ||||
Long Term Investments | ||||
Other Long Term Assets | ||||
Total Assets | 2,196 | 2,646 | 4,815 | 4,215 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 207 | 386 | 683 | 666 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 647 | 746 | 1,046 | 1,011 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | 1,549 | 1,900 | 3,770 | 3,203 |
Total Liabilities & Shareholders' Equity | 2,196 | 2,646 | 4,815 | 4,215 |
Total Common Shares Outstanding |